Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of FHND1002 Granules in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT07138014 is registered in ClinicalTrials.gov with Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07138014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07138014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of FHND1002 Granules in Patients With Amyotrophic Lateral Sclerosis (ALS)
Lead sponsor
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2025
Completion date
March 1, 2028
Enrollment
180 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis (als)